Exemestane (Aromasin)
Prescription aromatase inhibitor for breast cancer that bodybuilders use to keep estrogen low; banned on the anti-doping list.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Anastrozol vs Letrozol vs ExemestaneDETAILED OVERVIEW
What is Exemestane (Aromasin)?
Exemestane (Aromasin) is a prescription medicine for estrogen-sensitive breast cancer in women after menopause. It has been approved in the United States since 1999, and in the EU as well. Bodybuilders and other athletes use it to keep estrogen low while taking muscle-building steroids. It is banned year-round on the anti-doping list.
It blocks an enzyme called aromatase, which makes estrogen from testosterone. It binds to the enzyme permanently and disables it, so the effect wears off only when the body has made new enzyme, which takes about 5–7 days. Typical side effects are joint and muscle pain, hot flashes and tiredness; if estrogen drops too far, low mood, reduced sex drive and erection problems can appear. It lowers HDL cholesterol and, with long-term use, raises the risk of bone thinning. It must not be used in pregnancy, because it can harm the baby.
Mechanism
Steroidal "suicide" (irreversible covalent) CYP19 aromatase inhibitor – a single dose permanently inactivates a portion of the pool
Half-life
~27 h (parent), ~24-48 h active metabolite; pharmacodynamic effect 5-7 days
Onset
E2 reduction measurable 12-24 h, full effect 3-5 days
Legal status
FDA + EMA Rx, HU + PL approved, WADA S4.1 banned
No anecdote collected yet.
Data console
Lab data
Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C . Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.. Eur J Cancer.
Miller WR, Anderson TJ, Evans DB . An integrated view of aromatase and its inhibition.. J Steroid Biochem Mol Biol.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J . Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized, placebo-controlled study.. Eur J Cancer.
Lønning PE . Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.. Breast Cancer Res Treat.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Joint and muscle pain (arthralgia, myalgia) and stiffness, a hallmark estrogen-deprivation effect of the AI class.
- Hot flushes, sweating and fatigue, vasomotor symptoms of rapid estrogen decline.
- Over-suppressed estradiol (crashed E2): low mood, reduced libido, dry/cracking joints, depression and erectile difficulty.
- Adverse lipid shift: lowered HDL (~10-15%) and slight LDL rise, which compounds on top of an AAS stack.
- Reduced bone mineral density (osteopenia/osteoporosis risk) and higher fracture tendency with prolonged estrogen suppression.
- Mild androgenic effects from the 17-hydro-exemestane metabolite: acne and oily skin may increase, especially stacked with aromatizing steroids.
- Headache, insomnia, dizziness and gastrointestinal complaints (nausea), common and usually mild.
- Rarely elevated liver enzymes (ALT/AST) and bilirubin; as an oral agent, dual liver monitoring is warranted alongside 17-alpha-alkylated AAS.
Contraindications · 7
- Pregnancy and breastfeeding: exemestane is teratogenic and fetotoxic (Pregnancy Category X), absolutely contraindicated.
- Premenopausal women: ineffective due to intact ovarian aromatase and may cause ovulatory/hormonal disruption and virilization, contraindicated.
- Known hypersensitivity to exemestane or any excipient of the formulation.
- Severe hepatic (Child-Pugh C) or renal impairment: disturbed metabolism and clearance with increased exposure, caution/contraindication.
- Pre-existing osteoporosis or high bone-loss risk: estrogen suppression accelerates bone loss, avoid without prior DEXA and bone protection.
- Concurrent estrogen-containing agents (HRT, phytoestrogens): they negate the aromatase inhibition, an interaction to avoid.
- Strong CYP3A4 inducers (rifampicin, carbamazepine, St. John's wort) reduce efficacy; avoid prophylactic AI use without E2 baseline bloodwork due to crashed-E2 risk.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C
An integrated view of aromatase and its inhibition.
Miller WR, Anderson TJ, Evans DB
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized, placebo-controlled study.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J
Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Telegram
Have a question about Exemestane (Aromasin)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


